Keyphrases
Food Allergy
58%
Asthma
50%
Omalizumab
44%
Placebo
31%
Peanut Allergy
25%
Asthma Exacerbation
25%
Allergy
22%
Epicutaneous Immunotherapy
21%
In Vitro Test
21%
Eosinophilic Esophagitis
21%
Allergen-specific IgE
20%
Milk
20%
Allergic Diseases
19%
Inner child
19%
Aeroallergens
18%
Randomized Clinical Trial
17%
Persistent Asthma
17%
Prurigo Nodularis
16%
Immunology
16%
Primary Immunodeficiency
16%
Data Commons
16%
T Cells
16%
Anaphylaxis
16%
Six-food Elimination Diet
15%
Placebo-controlled
15%
Inner City
14%
Serum IgE
14%
African American
13%
Allergen
13%
Asthma Severity
13%
African American children
13%
Placebo Groups
13%
Oral Food Challenge
13%
Severe Combined Immunodeficiency
12%
Itch
12%
In Vitro Testing
12%
Emergency Preparedness
12%
Peanut
12%
Numeric Rating Scale
11%
Nephelometry
11%
High Risk
11%
Nasal
11%
Desensitization
11%
Rhinitis
11%
Urban children
10%
Risk Factors
10%
Tree nuts
10%
Clinical Trials
10%
Phase II Trial
10%
Airway Epithelial Cells
10%
Immunology and Microbiology
Asthma
100%
Immunoglobulin E
56%
Allergen
49%
Omalizumab
43%
Food Allergy
37%
Immunotherapy
34%
Asthma Exacerbation
24%
Immunodeficiency
23%
Sensitization
22%
Peanut Allergy
21%
Radioallergosorbent Test
16%
T Cell
14%
Adolescence
13%
Immunoglobulin E Antibody
13%
Anaphylaxis
12%
Arm
12%
Lymphocytopenia
12%
DNA Methylation
11%
Rhinitis
10%
Severe Combined Immunodeficiency
10%
Allele
10%
Food Allergen
10%
Allergic Asthma
8%
Mepolizumab
8%
Resting Energy Expenditure
8%
Multi-Omics
8%
Blattella germanica
8%
Methylation
8%
Forced Expiratory Volume
8%
Immune Disorder
8%
Superoxide
8%
B Cell
8%
Gene Expression
6%
Neutrophil
6%
Hypersensitive Response
5%
Promoter Region
5%
Medicine and Dentistry
Food Allergy
47%
Asthma
42%
Placebo
29%
Immunoglobulin E
25%
Pediatrics
18%
Immune Deficiency
17%
Eosinophilic Esophagitis
16%
Elimination Diet
16%
Randomized Clinical Trial
16%
Prurigo nodularis
16%
Adolescence
13%
Anaphylaxis
13%
Asthma Exacerbation
12%
T Cell
12%
Lymphocytopenia
12%
Pruritus
12%
Lung
12%
Numeric Rating Scale
11%
Prevalence
11%
Rhinitis
10%
Severe Combined Immunodeficiency
10%
Dupilumab
9%
Clinical Trial
9%
Quality of Life
9%
Eosinophilic
8%
Wiskott Aldrich Syndrome
8%
Resting Energy Expenditure
8%
Failure to Thrive
8%
Predictor
8%
Group Trial
8%
Chinese Herbal Medicine
8%
Transdermal Patch
8%
Neutrophil
8%
Superoxide
8%
Immune Response
8%
Post-Hoc Analysis
8%
Immunotherapy
8%
Mepolizumab
8%
Tamsulosin
8%
DNA Methylation
8%
Milk Allergy
8%
Ingestion
8%
Allergen
7%
Infection
7%
Forced Expiratory Volume
6%
Guanosine Triphosphate
6%
Particular Matter 2.5
6%
Hypermetabolism
5%
Intention-to-Treat Analysis
5%
Eosinophil
5%
